Skip to main content

Meridian Bio Q3 Revenues Increase 12 Percent

NEW YORK (GenomeWeb News) – Meridian Bioscience said today that sales in its fiscal third quarter rose 12 percent year over year.

For the three months ended June 30, the company has $47.1 million in sales, up from $41.9 million a year ago, edging out the average Wall Street estimate of $47.0 million.

In a statement, CEO John Kraeutler said that Illumigene product sales were up 36 percent year over year.

Profit was $10.2 million, or$.24 per share, compared to a profit of $8.6 million, or$.21 per share. Adjusted EPS was $.25, beating the average Wall Street estimate of $.22.

R&D was essentially flat at $2.7 million, while SG&A costs of $12.2 million was up 3 percent from $11.8 million a year ago.

Meridian Bio finished the quarter with $40.4 million in cash and equivalents.

The company declared a quarterly cash dividend of $.19 per share for the fiscal third quarter, payable on Aug. 15 to shareholders of record Aug. 5.

For the full-year, sales are expected to be in the range of $190 million to $194 million. EPS is expected in the range of $.86 and $.91.

The Scan

UK Funds to Stay Ahead of Variants

The UK has announced a further £29.3 million to stay on top of SARS-CoV-2 variants, the Guardian reports.

Push for Access

In a letter, researchers in India seek easier access to COVID-19 data, Science reports.

Not as Cold

Late-stage trial results are expected soon for an RNA-based vaccine that could help meet global demand as it does not require very cold storage, the New York Times writes.

Genome Research Papers on Microbes' Effects on Host Transfer RNA, Honeybee Evolution, Single-Cell Histones

In Genome Research this week: influence of microbes on transfer RNA patterns, evolutionary relationships of honeybees, and more.